Kymera Announces Positive Results from Phase 1 Clinical Trial Evaluating KT-474 in Patients with HS…
KT-474 Phase 1 clinical data in HS and AD patients demonstrate robust IRAK4 knockdown in blood and active skin lesions and systemic suppression of proinflammatory cytokines and chemokines with a favorable safety profile Clinical endpoints…